Thyroid Cancer Risk Related to Radiotherapy for Childhood Cancer

Radiotherapy used to treat childhood cancers may contribute to survivors developing subsequent thyroid cancer, say researchers from the US NCI in the June 11 journal Lancet. Chemotherapy given for the original cancer had no impact on later thyroid cancer risk, nor did it modify the risk found from radiotherapy.



LIN Note: radiotherapy is often used in childhood lymphoma treatment.



"Childhood cancer survivors with a history of radiation exposure to the chest, neck, or head should be considered at risk for thyroid cancer and these patients should have yearly thyroid and neck examinations," the authors said.



By correlating the dose of cumulative radiation received with the occurrence of secondary thyroid cancer, the researchers found evidence for decline in risk at high doses that earlier studies could not. The risk varies with the radiation that the researchers calculated was absorbed by the patient's thyroid gland at the time of original treatment. From 1 Gy up to 20 Gy, the risk increases, peaking between 20 and 29 Gy. Above 30 Gy and up to 50 Gy the risk decreases, "consistent with a cell-killing effect at high doses," said the authors. The study results do not have implications for clinical treatment decisions with regard to childhood cancers because other serious late effects of radiotherapy and chemotherapy do show increasing risk with increasing doses. NCI Bulletin

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap